Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
NCT: NCT07281924 · RECRUITING
Brief Summary
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Frequently Asked Questions
What is Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis?
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis is a clinical trial registered under NCT07281924. Current status: RECRUITING.
What is the status of NCT07281924?
The current status of NCT07281924 (Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis) is: RECRUITING.
When did Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis start?
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.